NCT02001688View on ClinicalTrials.gov

"Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

May 31, 2016

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

Kamada-AAT for Inhalation, 80mg

DRUG

Placebo

DRUG

Kamada-AAT for Inhalation, 160mg

Trial Locations (2)

32610

University of Florida, Pulmonary, Critical Care & Sleep Medicine, Gainesville

75708

The University of Texas Health Science Center at Tyler Center for Clinical Research, Tyler

All Listed Sponsors
lead

Kamada, Ltd.

INDUSTRY

NCT02001688 - "Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" | Biotech Hunter | Biotech Hunter